

REMARKS

A Continued Prosecution Application was filed for the above-referenced application on December 20, 2001 in which Claims 8, 10 and 19-20 are pending. By the above amendment, new Claim 21 has been added. Support for new Claim 21 is found throughout the specification, in one such instance, in claims 1 and 9, and on page 16 as originally filed. After entry of the amendment, Claims 8, 10 and 19-21 will remain pending and under consideration.

Early favorable action is respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,



Mary A. Appollina
Attorney for Applicants
Reg. No. 34,087

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-3742
Dated: January 7, 2002

Attachment

Version with Markings to Show Changes Made

21. (New) A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a therapeutically effective amount of a compound of formula



a N-oxide, an addition salt, a quaternary amine or a stereocchemically isomeric form thereof, wherein

$-b^1=b^2-C(R^{2a})=b^3-b^4=$ represents a bivalent radical of formula

$-CH=CH-C(R^{2a})=CH-CH=$ (b-1);

$-N=CH-C(R^{2a})=CH-CH=$ (b-2);

$-CH=N-C(R^{2a})=CH-CH=$ (b-3);

$-N=CH-C(R^{2a})=N-CH=$ (b-4);

$-N=CH-C(R^{2a})=CH-N=$ (b-5);

$-CH=N-C(R^{2a})=N-CH=$ (b-6);

$-N=N-C(R^{2a})=CH-CH=$ (b-7);


q is 0, 1, 2; or where possible q is 3 or 4;

R¹ is hydrogen; aryl; formyl; C₁-alkylcarbonyl; C₁-alkyl; C₁-alkyloxycarbonyl; C₁-alkyl substituted with formyl, C₁-alkylcarbonyl, C₁-alkyloxycarbonyl, C₁-alkylcarbonyloxy; C₁-alkyloxyC₁-alkylcarbonyl substituted with C₁-alkyloxycarbonyl;

R²a is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl, C₁-alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl, C₂-alkenyl substituted with cyano, or C₂-alkynyl substituted with cyano;

each R² independently is hydroxy, halo, C₁-alkyl optionally substituted with cyano or $-C(=O)R^6$, C₃-7cycloalkyl, C₂-alkenyl optionally substituted with one or more halogen atoms or cyano, C₂-alkynyl optionally substituted with one or more halogen

atoms or cyano, C_1 -alkyloxy, C_1 -alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C_1 -alkyl)amino, polyhalomethyl, polyhalomethoxy, polyhalomethylthio, $S(=O)_pR^6$, $-NH-S(=O)_pR^6$, $-C(=O)R^6$, $-NHC(=O)H$, $-C(=O)NHNH_2$, $-NHC(=O)R^6$, $-C(=NH)R^6$ or a radical of formula



wherein each A independently is N, CH or CR^6 ;

B is NH, O, S or NR^6 ;

p is 1 or 2; and

R^6 is methyl, amino, mono- or dimethylamino or polyhalomethyl;

L is C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-7} cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from

- * C_{3-7} cycloalkyl,
- * indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C_1 -alkyl, hydroxy, C_1 -alkyloxy, cyano, amino-carbonyl, nitro, amino, polyhalomethyl, polyhalomethoxy and C_1 -alkylcarbonyl,
- * phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R^2 ; or

L is $-X-R^3$ wherein

R^3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R^2 ; and

X is $-NR^1-$, $-NH-NH-$, $-N=N-$, $-O-$, $-C(=O)-$, $-CHOH-$, $-S-$, $-S(=O)-$ or $-S(=O)_2-$;

Q represents hydrogen, C₁₋₆alkyl, halo, polyhaloC₁₋₆alkyl or -NR⁶R⁵; and

R⁴ and R⁵ are each independently selected from hydrogen, hydroxy, C₁₋₁₂alkyl, C₁₋₁₂alkyloxy, C₁₋₁₂alkylcarbonyl, C₁₋₁₂alkyloxycarbonyl, aryl, amino, mono- or di(C₁₋₁₂alkyl)amino, mono- or di(C₁₋₁₂alkyl)aminocarbonyl wherein each of the aforementioned C₁₋₁₂alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, mono- or di(C₁₋₆alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, aryl and Het; or

R⁴ and R⁵ taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C₁₋₁₂alkyl)aminoC₁₋₆alkylidene;

Y represents hydroxy, halo, C₃₋₇cycloalkyl, C₂₋₆alkenyl optionally substituted with one or more halogen atoms, C₂₋₆alkynyl optionally substituted with one or more halogen atoms, C₁₋₆alkyl substituted with cyano or -C(=O)R⁶, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C₁₋₆alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶ or aryl;

aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, cyano, nitro, polyhaloC₁₋₆alkyl and polyhaloC₁₋₆alkyloxy;

Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is

selected from pyrrolyl, furanyl, thieryl, pyridinyl,
pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said
aromatic heterocyclic radical may optionally be substituted
with hydroxy.